Objective: To determine the cost-effectiveness of the treatment of advanced hormone-dependent prostate cancer with degarelix compared to luteinizing hormone-releasing hormone (LHRH) agonists in the UK using the latest available evidence and the model submitted to AWMSG.
Methods: A cost-effectiveness model was developed from the perspective of the UK National Health Service evaluating monthly injection of degarelix against 3-monthly leuprorelin therapy plus anti-androgen flare cover for the first-line treatment of patients with advanced (locally advanced or metastatic) hormone-dependent prostate cancer. A Markov process model was constructed using the patient population characteristics and efficacy information from the CS21 Phase III clinical trial and associated extension study (CS21A). The intention-to-treat (ITT) population and a high-risk sub-group with a PSA level >20 ng/mL were modeled.
Results: In the base-case analysis using the patient access scheme (PAS) price, degarelix was dominant compared to leuprorelin with cost savings of £3633 in the ITT population and £4310 in the PSA > 20 ng/mL sub-group. The chance of being cost-effective was 95% in the ITT population and 96% in the PSA > 20 ng/mL sub-group at a threshold of £20,000 per quality-adjusted life-year (QALY). In addition, degarelix remained dominant when PSA progression was assumed equal and only the benefits of preventing testosterone flare were taken into account. Treatment with degarelix also remained dominant in both populations when the list price was used. The additional investment required to treat patients with degarelix could be offset in 19 months for the ITT population and 13 months for the PSA > 20 ng/mL population. The model was most sensitive to the hazard ratio assumed for PSA progression between degarelix and leuprorelin and the quality-of-life (utility) of patients receiving palliative care.
Conclusion: Degarelix is likely to be cost-effective compared to leuprorelin plus anti-androgen flare cover in the first-line treatment of advanced hormone-dependent prostate cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3111/13696998.2014.893240 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Human Cytochrome P450 Cancer-Related Metabolic Activities and Gene Polymorphisms: A Review.
Cells
November 2024
Independent Researcher, 108815 Moscow, Russia.
Background: Cytochromes P450 (CYPs) are heme-containing oxidoreductase enzymes with mono-oxygenase activity. Human CYPs catalyze the oxidation of a great variety of chemicals, including xenobiotics, steroid hormones, vitamins, bile acids, procarcinogens, and drugs.
Findings: In our review article, we discuss recent data evidencing that the same CYP isoform can be involved in both bioactivation and detoxification reactions and convert the same substrate to different products.
Triplet therapy for metastatic castration-sensitive prostate cancer: Rationale and clinical evidence.
Int J Urol
December 2024
Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Prostate cancer (PC) growth is hormone-dependent and it frequently develops distant metastases as disease progresses. Patients with metastatic castration-sensitive prostate cancer (mCSPC) initially respond to androgen deprivation therapy (ADT) but eventually become refractory and develop metastatic castration-resistant prostate cancer (mCRPC). Castration-resistance is associated with high lethality and metastases confer poor prognosis, therefore unmet needs in treatment for mCSPC remain high.
View Article and Find Full Text PDFGWAS and 3D chromatin mapping identifies multicancer risk genes associated with hormone-dependent cancers.
PLoS Genet
November 2024
Cancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Hormone-dependent cancers (HDCs) share several risk factors, suggesting a common aetiology. Using data from genome-wide association studies, we showed spatial clustering of risk variants across four HDCs (breast, endometrial, ovarian and prostate cancers), contrasting with genetically uncorrelated traits. We identified 44 multi-HDC risk regions across the genome, defined as overlapping risk regions for at least two HDCs: two regions contained risk variants for all four HDCs, 13 for three HDCs and 28 for two HDCs.
View Article and Find Full Text PDFBulk mRNA-sequencing data of the estrogen and androgen responses in the human prostate cancer cell line VCaP.
Data Brief
December 2024
Department of Molecular Medicine, Faculty of Medicine, Université Laval, 1050 avenue de la Médecine, Québec City, Québec G1V 0A6, Canada.
Prostate cancer is a hormone-dependent disease that relies on the androgen signaling, as well as on the estrogen signaling, for growth and survival. To identify the genes regulated by these sex-steroid hormones in the human prostate cancer cell line VCaP, these cells were treated for 24 h with either androgens and/or estrogens. Then, the RNA of each sample was purified for sequencing to generate bulk mRNA-seq data.
View Article and Find Full Text PDFA Systematic Review and Meta-Analysis of the Effects of Dietary Isoflavones on Female Hormone-Dependent Cancers for Benefit-Risk Evaluation.
Phytother Res
December 2024
Department of Cell and Molecular Biology, University of Mississippi Medical Center, Jackson, MS, USA.
Female hormone-dependent cancers depend on estrogen for their growth. Numerous studies have explored the antitumor effect of dietary isoflavones on female hormone-dependent cancers. Still, few clinical evidence supports the use of isoflavones in female hormone-dependent cancer patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!